Last updated: September 5, 2026
Chlorpheniramine polistirex and hydrocodone polistirex are the active ingredients in Tussionex Pennkinetic Extended-Release Suspension, a prescription cough medicine marketed in the United States. The product combines an opioid antitussive with an antihistamine in a 12-hour liquid formulation. Its commercial profile is mature and declining: historical patent protection has expired, generic competition is permitted, opioid prescribing restrictions limit demand, and product-specific revenue is not publicly disclosed by the current private manufacturer, Tris Pharma.
What is chlorpheniramine polistirex and hydrocodone polistirex?
Tussionex contains hydrocodone polistirex and chlorpheniramine polistirex in an extended-release oral suspension.
| Product attribute |
Detail |
| Brand |
Tussionex Pennkinetic Extended-Release Suspension |
| Active ingredients |
Hydrocodone polistirex and chlorpheniramine polistirex |
| Strength per 5 mL |
Hydrocodone polistirex equivalent to 10 mg hydrocodone; chlorpheniramine polistirex equivalent to 8 mg chlorpheniramine |
| Dosage form |
Extended-release oral suspension |
| Dosing interval |
Generally every 12 hours |
| FDA application |
NDA 019111 |
| Therapeutic use |
Temporary relief of cough and upper-respiratory symptoms |
| Controlled-substance status |
Schedule II hydrocodone product |
| Current commercial owner or marketer |
Tris Pharma, based on current product labeling and DailyMed records |
| Primary market |
United States |
The polistirex resin system controls release of the active ingredients. The formulation differentiates the product from immediate-release hydrocodone cough syrups by extending exposure over approximately 12 hours. The product label warns about respiratory depression, misuse, abuse, addiction, overdose, and interaction with central nervous system depressants. (U.S. Food and Drug Administration [FDA], 2023a)
What is the FDA regulatory status of Tussionex?
Tussionex is an approved prescription drug regulated under an original new drug application. It is not a biologic and does not face biosimilar substitution. The relevant regulatory pathway for competitors is an abbreviated new drug application, or ANDA, when the applicant demonstrates pharmaceutical equivalence and bioequivalence to the reference product.
The product’s regulatory position is constrained by later FDA safety actions affecting prescription opioid cough medicines. In 2018, FDA required labeling changes for prescription cough and cold products containing codeine or hydrocodone. The products were restricted to adults 18 years and older because of risks associated with opioid exposure in children and adolescents. (FDA, 2018)
The current label also limits pediatric use. Tussionex is contraindicated in children younger than six years, and the 2018 FDA action effectively removed routine pediatric use for patients under 18.
What is the Orange Book status of hydrocodone polistirex and chlorpheniramine polistirex?
The reference product is listed in the FDA Orange Book under NDA 019111. Historical patent protection covering the extended-release resin formulation has expired. The commercial issue is therefore no longer a conventional patent monopoly. Market access depends on FDA approval, manufacturing capacity, controlled-substance compliance, formulation performance, and payer demand.
Orange Book records should be checked against the current edition for active patent and exclusivity entries. No commercially meaningful current exclusivity period is associated with the original Tussionex approval. The product is an old small-molecule combination, not an eligible new chemical entity with remaining five-year exclusivity.
What patents protect Tussionex?
The main historical patent dispute involved U.S. Patent No. 6,024,980, which covered aspects of controlled-release pharmaceutical compositions containing hydrocodone and chlorpheniramine. The patent was associated with Tussionex and was asserted against generic applicants.
| Patent |
Subject matter |
Historical relevance |
Current status |
| U.S. Patent No. 6,024,980 |
Controlled-release hydrocodone and chlorpheniramine composition |
Central historical formulation patent |
Expired |
| Earlier formulation and resin patents |
Sustained-release drug-resin systems |
Supported the Pennkinetic delivery concept |
Expired or no longer commercially blocking |
| Current Orange Book patents |
Product-specific listed claims |
Determine whether an ANDA applicant must address an active patent |
No material current barrier identified for the legacy product |
The patent estate was narrower than the estate surrounding newer branded medicines. It focused on the delivery system and combination formulation rather than a novel active pharmaceutical ingredient. Once the primary formulation patent expired, competitors could pursue equivalent extended-release suspensions without facing a live composition-of-matter patent.
When did Tussionex lose exclusivity?
Tussionex lost effective patent exclusivity in the late 2010s. The key formulation patent, U.S. Patent No. 6,024,980, reached the end of its patent term around 2017 to 2018, including potential pediatric extension. The original FDA approval dates to the early 1980s, so statutory drug exclusivity had expired decades earlier.
| Milestone |
Approximate timing |
Commercial effect |
| Original FDA approval |
Early 1980s |
Established the reference product |
| Original drug exclusivity |
Expired decades ago |
No continuing NCE protection |
| Formulation patent litigation |
Late 2000s to early 2010s |
Delayed or complicated generic entry |
| Key patent expiration |
Approximately 2017-2018 |
Removed the principal patent barrier |
| Current period |
2020s |
Mature brand, generic and authorized-generic competition |
The exact date relevant to a particular ANDA depends on the patent term, patent-term adjustment, pediatric extension, and any court judgment. The practical conclusion is unchanged: the principal Tussionex formulation patent no longer blocks generic development.
Which companies challenged Tussionex patents?
Generic drug companies challenged the product through ANDA filings and Paragraph IV patent certifications. Public litigation involving Tussionex included disputes between the branded-product rights holder and generic applicants, including Hi-Tech Pharmacal and other generic industry participants.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. Filing a Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act and can create a 30-month stay of FDA approval, subject to statutory exceptions.
The historical litigation affected timing rather than long-term market structure. Once the relevant patents expired, a generic applicant no longer needed to win a patent case to obtain approval. It needed to satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing quality, and controlled-substance compliance.
What formulation patents protect hydrocodone polistirex and chlorpheniramine polistirex?
The formulation’s technical value comes from the drug-resin complex and extended-release suspension system. Key formulation attributes include:
- Controlled release over an approximately 12-hour interval.
- Uniform dispersion of resin-bound drug in a liquid vehicle.
- Dose delivery through a measured oral suspension.
- Combined delivery of hydrocodone and chlorpheniramine.
- Stability of the suspension during storage and use.
These attributes create development barriers even after patent expiration. An ANDA applicant must demonstrate that its product performs adequately, remains physically and chemically stable, and delivers comparable exposure. Liquid extended-release products can be more difficult to reproduce than conventional immediate-release tablets because particle size, resin loading, viscosity, sedimentation, redispersibility, and preservative systems can affect performance.
The formulation barrier is therefore technical rather than legal. It can reduce the number of approved suppliers, but it does not preserve premium pricing in the way an active patent does.
How strong is the patent estate for Tussionex?
The current patent estate is weak from an exclusivity perspective.
| Factor |
Assessment |
| Composition-of-matter protection |
None of practical current value |
| NCE exclusivity |
Expired |
| Formulation patents |
Historical patents expired |
| Method-of-use patents |
No material current barrier identified |
| Delivery-system differentiation |
Technically relevant but no longer patent-exclusive |
| Trademark value |
Still potentially relevant to prescriber and pharmacy recognition |
| Manufacturing complexity |
Moderate for an extended-release liquid |
| Regulatory barrier |
Moderate because the product contains a Schedule II opioid |
| Litigation risk from legacy patents |
Low after expiration |
The product can retain commercial value through brand recognition, distribution relationships, manufacturing know-how, and supply reliability. Those factors are weaker than patent exclusivity and are vulnerable to generic substitution.
What is the market outlook for hydrocodone cough medicine?
The market outlook is structurally negative. Demand is affected by four forces:
- Opioid stewardship has reduced prescribing of hydrocodone cough products.
- FDA labeling changes restrict use in patients under 18.
- Physicians can choose non-opioid antitussives and supportive care.
- Generic entry limits branded pricing power.
Hydrocodone cough medicines remain clinically relevant for selected adult patients, but they occupy a narrower treatment segment than in prior decades. The combination with chlorpheniramine provides symptom coverage for cough and rhinorrhea, yet the opioid component creates prescribing and compliance burdens.
Retail demand is also seasonal. Respiratory illness cycles can produce winter volume increases, but seasonal spikes do not change the long-term erosion caused by generic substitution and declining opioid utilization.
What is the financial trajectory of Tussionex?
Product-specific revenue is not publicly reported by Tris Pharma. Tris is privately held and does not provide the same brand-level revenue disclosures as a public pharmaceutical company. Historical Tussionex revenue disclosures from prior owners are limited and are not a reliable basis for current valuation.
The financial trajectory can be characterized as follows:
| Period |
Financial profile |
| Pre-generic period |
Higher pricing and stronger brand capture, supported by formulation differentiation |
| Patent-challenge period |
Litigation expense, launch uncertainty, and possible channel inventory effects |
| Post-expiration period |
Lower net price, higher substitution, and fragmented supplier economics |
| Current mature period |
Seasonal demand, controlled-substance compliance costs, and limited pricing power |
Revenue exposure is likely modest relative to the portfolios of diversified pharmaceutical companies. The product’s value is more likely to reside in contribution margin, portfolio fit, and manufacturing utilization than in standalone growth.
For investors or acquirers, the relevant diligence questions are unit volume, generic share, net selling price, payer mix, controlled-substance quota availability, manufacturing cost, product liability reserves, and customer concentration. Public sources do not establish a current product-level revenue figure.
What generic launch risks exist?
A generic launch faces commercial and technical risks even though patent barriers have expired.
Regulatory and manufacturing risks
The applicant must manage:
- Controlled-substance registration and quota requirements.
- Schedule II recordkeeping and distribution controls.
- Extended-release bioequivalence.
- Suspension uniformity and dose reproducibility.
- Stability and preservative performance.
- Packaging and child-resistant closure requirements.
- Labeling consistency with the reference product.
Commercial risks
The main commercial risks are low market growth, limited adult prescribing, seasonal demand, reimbursement pressure, and potential competition from more than one generic supplier. A first generic may obtain favorable early share, but margins can compress quickly if additional manufacturers enter.
The market is also exposed to regulatory enforcement. Opioid distribution controls, suspicious-order monitoring, state prescribing limits, and pharmacy restrictions can affect supply and sales even when FDA approval remains active.
How does Tussionex compare with competing cough medicines?
| Product category |
Active ingredient |
Prescription status |
Abuse risk |
Competitive position |
| Tussionex |
Hydrocodone plus chlorpheniramine |
Prescription, Schedule II |
High |
Mature, declining |
| Benzonatate |
Non-opioid antitussive |
Prescription |
Lower than hydrocodone, but toxicity risk exists |
Established alternative |
| Dextromethorphan products |
Non-opioid antitussive |
Mostly OTC |
Lower at therapeutic use |
Broad consumer access |
| Codeine cough products |
Opioid antitussive |
Prescription, controlled substance |
High |
Regulatory pressure |
| Guaifenesin combinations |
Expectorant combinations |
Mostly OTC |
Low |
Large, lower-cost market |
Tussionex’s differentiation is its extended-release liquid format and combined opioid-antihistamine symptom control. Its disadvantages are controlled-substance restrictions, safety warnings, limited pediatric use, and generic pricing pressure.
What licensing deals affect the product?
The product has changed commercial hands over time. Tris Pharma became associated with Tussionex commercialization after acquiring or licensing rights from prior owners, including UCB-related product assets. Public disclosures do not provide a current, product-specific royalty rate, milestone schedule, or transfer-pricing structure.
The commercial rights structure matters because a legacy brand may involve separate ownership of the NDA, trademark, manufacturing rights, and distribution rights. These distinctions affect profitability and supply continuity but are not fully visible in public FDA records.
What is the geographic coverage of the product?
Tussionex is primarily a United States product. The FDA approval, Orange Book listing, Schedule II controls, and principal patent disputes are U.S.-specific. Equivalent hydrocodone-chlorpheniramine products may exist in other markets, but regulatory status, controlled-substance classification, patent rights, and commercial ownership must be assessed country by country.
The United States remains the principal jurisdiction for patent, regulatory, and market analysis because the reference product and the best-documented generic pathway are U.S.-based.
Key Takeaways
- Chlorpheniramine polistirex and hydrocodone polistirex are the active ingredients in Tussionex extended-release suspension.
- The product is an old Schedule II prescription medicine with no remaining new chemical entity exclusivity.
- The principal historical formulation patent, U.S. Patent No. 6,024,980, expired around 2017 to 2018.
- Patent litigation delayed or complicated historical generic entry but is no longer the main commercial barrier.
- Generic substitution, opioid prescribing restrictions, and FDA labeling changes have weakened the market.
- The extended-release liquid remains technically more difficult to reproduce than an immediate-release product.
- Tris Pharma is the current commercial company associated with the product, but it does not publicly disclose product-level revenue.
- Current value depends on brand recognition, manufacturing reliability, distribution, and contribution margin rather than patent exclusivity.
- The competitive threat comes from generic extended-release suspensions and non-opioid cough medicines.
- The principal risk is long-term volume and price erosion, not biosimilar competition.
Frequently Asked Questions
Is hydrocodone polistirex the same as hydrocodone bitartrate?
No. Hydrocodone polistirex is a resin-bound extended-release form of hydrocodone. Hydrocodone bitartrate is an immediate-release salt used in other prescription products. The dosage, release profile, and bioequivalence requirements differ.
Can pharmacies substitute a generic for Tussionex?
Substitution depends on the availability of an FDA-approved therapeutically equivalent product, state pharmacy law, payer policy, and the prescriber’s instructions. The pharmacist must confirm that the generic has the appropriate extended-release formulation and strength.
Does Tussionex have orphan-drug protection?
No. Tussionex is not an orphan drug, and its commercial position does not derive from orphan-drug exclusivity.
Is Tussionex still approved for children?
FDA labeling changes restrict prescription hydrocodone cough products to adults 18 years and older. Tussionex is also contraindicated in children younger than six years. Pediatric use should not be treated as a continuing commercial market for the product. (FDA, 2018; FDA, 2023a)
Could a new manufacturer obtain market exclusivity for a reformulated product?
A reformulated product could receive separate patents or regulatory exclusivity if it met applicable statutory standards. A conventional generic copy of the existing extended-release suspension would not receive new composition-of-matter exclusivity merely because a new company manufactures it.
References
-
U.S. Food and Drug Administration. (2018, January 11). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. https://www.fda.gov
-
U.S. Food and Drug Administration. (2023a). Tussionex Pennkinetic extended-release suspension prescribing information. Tris Pharma, Inc. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
-
U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,024,980: Controlled-release pharmaceutical compositions. https://patents.google.com
-
U.S. Drug Enforcement Administration. (2024). Controlled substances act: Schedule II controlled substances. https://www.deadiversion.usdoj.gov
